CORONAVIRUS - 2020

[RyNo_23]

$CRXM put out their Super 10K on Friday.

From page 11.

Gene Biotherapeutics’ research is focused on the design of an observational clinical study to evaluate if COVID-19 may exacerbate microvascular damage and perfusion impairment in patients with pre-existing coronary artery disease and cardiac reversible perfusion defects (“RPD”) prior to COVID-19 infection. We are proposing to assess the damage using SPECT (Single-Photon Emission Computed Tomography) imaging to evaluate changes in RPD as a result of COVID-19 infection. Demonstration of worsening perfusion due to COVID-19 would be supportive of the potential to evaluate the therapeutic benefit of the Generx [Ad5FGF-4] product candidate angiogenic gene therapy in this patient population.

https://www.otcmarkets.com/filing/html?id=14889579&guid=Xn9nUePH2yz_R3h

Only 49M OS - going much, much higher $$$